Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vistagen Therapeutics (VTGN) Shares Outstanding (Diluted Average) (2023 - 2025)

Historic Shares Outstanding (Diluted Average) for Vistagen Therapeutics (VTGN) over the last 7 years, with Q4 2025 value amounting to $42.2 million.

  • Vistagen Therapeutics' Shares Outstanding (Diluted Average) rose 3751.82% to $42.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $42.2 million, marking a year-over-year increase of 3751.82%. This contributed to the annual value of $30.9 million for FY2025, which is 5953.41% up from last year.
  • Per Vistagen Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $42.2 million for Q4 2025, which was up 3751.82% from $35.7 million recorded in Q3 2025.
  • Over the past 5 years, Vistagen Therapeutics' Shares Outstanding (Diluted Average) peaked at $42.2 million during Q4 2025, and registered a low of $7.0 million during Q1 2023.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $30.6 million (2024), whereas its average is $25.5 million.
  • As far as peak fluctuations go, Vistagen Therapeutics' Shares Outstanding (Diluted Average) soared by 31711.07% in 2024, and later skyrocketed by 433.69% in 2025.
  • Over the past 3 years, Vistagen Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $29.4 million in 2023, then rose by 4.5% to $30.7 million in 2024, then surged by 37.52% to $42.2 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $42.2 million in Q4 2025, compared to $35.7 million in Q3 2025 and $31.9 million in Q2 2025.